256 related articles for article (PubMed ID: 26675289)
1. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
[TBL] [Abstract][Full Text] [Related]
2. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
[TBL] [Abstract][Full Text] [Related]
3. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
[TBL] [Abstract][Full Text] [Related]
4. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
7. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
8. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
10. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
13. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
14. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Capasso A; Pitts TM; Klauck PJ; Bagby SM; Westbrook L; Kaplan J; Soleimani M; Spreafico A; Tentler JJ; Diamond JR; Arcaroli JJ; Messersmith WA; Eckhardt SG; Leong S
Anticancer Drugs; 2018 Oct; 29(9):827-838. PubMed ID: 30048249
[TBL] [Abstract][Full Text] [Related]
15. Parecoxib: an enhancer of radiation therapy for colorectal cancer.
Xiong W; Li WH; Jiang YX; Liu S; Ai YQ; Liu R; Chang L; Zhang M; Wang XL; Bai H; Wang H; Zheng R; Tan J
Asian Pac J Cancer Prev; 2015; 16(2):627-33. PubMed ID: 25684498
[TBL] [Abstract][Full Text] [Related]
16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
20. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
